Your browser doesn't support javascript.
loading
Pathogenic signaling in multiple myeloma.
Bolomsky, Arnold; Young, Ryan M.
Afiliación
  • Bolomsky A; National Institutes of Health, National Cancer Institute, Center for Cancer Research, Lymphoid Malignancies Branch, Bethesda MD.
  • Young RM; National Institutes of Health, National Cancer Institute, Center for Cancer Research, Lymphoid Malignancies Branch, Bethesda MD. Electronic address: youngrm@nih.gov.
Semin Oncol ; 49(1): 27-40, 2022 02.
Article en En | MEDLINE | ID: mdl-35125242
Multiple myeloma is a common hematological malignancy of plasma cells, the terminally differentiated B cells that secrete antibodies as part of the adaptive immune response. Significant progress has been made in treating multiple myeloma, but this disease remains largely incurable, and most patients will eventually suffer a relapse of disease that becomes refractory to further therapies. Moreover, a portion of patients with multiple myeloma present with disease that is refractory to all treatments from the initial diagnosis, and no current therapeutic approaches can help. Therefore, the task remains to advance new therapeutic strategies to help these vulnerable patients. One strategy to meet this challenge is to unravel the complex web of pathogenic signaling pathways in malignant plasma cells and use this information to design novel precision medicine strategies to assist these patients most at risk.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Semin Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Semin Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos